Silence Therapeutics (SLN) Total Non-Current Liabilities (2019 - 2024)
Silence Therapeutics' Total Non-Current Liabilities history spans 6 years, with the latest figure at -$75.3 million for Q3 2024.
- On a quarterly basis, Total Non-Current Liabilities rose 0.8% to -$75.3 million in Q3 2024 year-over-year; TTM through Sep 2024 was -$75.3 million, a 0.8% increase, with the full-year FY2023 number at -$73.2 million, down 193.21% from a year prior.
- Total Non-Current Liabilities hit -$75.3 million in Q3 2024 for Silence Therapeutics, down from -$73.4 million in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for SLN hit a ceiling of $97.7 million in Q4 2021 and a floor of -$90.0 million in Q1 2022.
- Historically, Total Non-Current Liabilities has averaged -$48.5 million across 5 years, with a median of -$75.3 million in 2024.
- Biggest five-year swings in Total Non-Current Liabilities: soared 239.82% in 2020 and later crashed 198.35% in 2023.
- Tracing SLN's Total Non-Current Liabilities over 5 years: stood at $67.8 million in 2020, then surged by 44.17% to $97.7 million in 2021, then dropped by 23.81% to $74.5 million in 2022, then crashed by 198.35% to -$73.2 million in 2023, then dropped by 2.83% to -$75.3 million in 2024.
- Business Quant data shows Total Non-Current Liabilities for SLN at -$75.3 million in Q3 2024, -$73.4 million in Q2 2024, and -$71.4 million in Q1 2024.